About this trial
Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals.
In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.
Eligibility criteria
Qualifiers
Signed informed consent form
Patients with immunosuppression either by treatment or underlying diseases
Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations
Age of 18 years or older
Disqualifiers
Patients unwilling/ineligible for vaccination under current recommendations
Trial design
Treatments tested in this trial
- Not listed